Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09

Ko RH et al. – This study generally confirms a 40% CR rate for second and subsequent relapse, but our remission rate for early first relapse seems better than that reported in the literature (83% v approximately 70%). Our data may allow useful modeling of an expected remission rate for any population of patients who experience relapse.

Methods

Retrospective cohort review of patients with relapsed and refractory ALL previously treated at TACL institutions between years of 1995 and 2004
Data regarding initial and relapsed disease characteristics, disease response, and survival collected and compared with those of published reports

Results

Complete remission (CR) rates (mean ± SE) were 83% ± 4% for early first marrow relapse, 93% ± 3% for late first marrow relapse, 44% ± 5% for second marrow relapse, and 27% ± 6% for third marrow relapse
Five-year DFS rates in CR2 and CR3 were 27% ± 4% and 15% ± 7% respectively

<< Previous
Randomized phase III trial on gemcitabine versus mytomicin in...

Next >>
Novel agents for the treatment of adenocarcinoma of the pancreas